



## Ansell FY26 Half Year Results

16 February 2026

# Disclaimer and Non-IFRS Measures

The following presentation has been prepared by Ansell Limited (Ansell or the Company) for information purposes only. The information contained in this presentation is a summary only and does not purport to be complete. It should be read in conjunction with Ansell's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at [www.asx.com.au](http://www.asx.com.au).

This presentation may contain forward-looking statements or statements of opinion. These statements can be identified by the use of forward-looking terminology such as 'may', 'will', 'should', 'expect', 'intend', 'anticipate', 'estimate', 'continue', 'assume', or 'forecast' or comparable terminology. These forward-looking statements are current only as at the date of this presentation. Although Ansell believes these forward-looking statements to be reasonable, they are not certain and involve unknown risks and assumptions (including many that may be outside of the control of Ansell). No representation or warranty (express or implied) is made regarding the accuracy, completeness or reliability of the forward-looking statements or opinion or the assumptions on which either are based. All such information is, by its nature, subject to significant uncertainties outside of the control of the Company. Subject to disclosure requirements, Ansell is under no obligation to update any forward-looking statements contained in this presentation.

Ansell, its related bodies corporate and any of its or their respective officers, directors, employees, agents or advisers (Ansell Parties), do not make any representation or warranty, express or implied, in relation to the accuracy, reliability or completeness of the information contained herein, and to the maximum extent permitted by law disclaim any responsibility and liability flowing from the use of this information by any party. To the maximum extent permitted by law, the Ansell Parties do not accept any liability to any person, organisation or entity for any loss or damage arising from the use of this presentation or its contents or otherwise arising in connection with it.

The information included in this presentation is not intended to be relied upon and is not investment or financial product advice. This presentation is not and should not be considered as an offer or recommendation with respect to the subscription for, purchase or sale of any security and neither this document, nor anything in it shall form the basis of any contract or commitment. Before making any investment decision, you should seek appropriate financial advice, which may take into account your particular investment needs, objectives and financial circumstances. Past performance is no guarantee of future performance. The statements in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Ansell.

## NON-IFRS MEASURES

Ansell's financial results are reported under International Financial Reporting Standards (IFRS). This release includes certain non-IFRS measures including EBITDA, EBIT, GPADE, SG&A, EBIT and GPADE Margin, Adjusted EPS, Operating Cash Flow, Cash Conversion, Organic Constant Currency and Adjusted Sales Growth. These measures are presented to enable understanding of the underlying performance of the Company without the impact of non-trading items and foreign currency impacts. Non-IFRS measures have not been subject to audit or review.

# Contents

1

## Performance Overview

**Neil Salmon**

(Retiring Chief Executive Officer)

Double-digit earnings growth in subdued market conditions

On track to offset effects of higher US tariffs



2

## Key Growth Drivers & Sustainability Update

**Neil Salmon**

Foundations in place for long term growth  
Continued success with new products and enhancement of services offering



3

## Financial Results

**Brian Montgomery**

(Chief Financial Officer)

Strong expansion in GPADE Margin driving higher EBIT, significant balance sheet flexibility



4

## FY26 Outlook

**Nathalie Ahlström**

(Incoming Chief Executive Officer)

Previously announced on-market share buyback program to continue in FY26 H2  
Maintaining guidance range for FY26 Adjusted EPS<sup>1</sup>



5

## Q&A

**Neil Salmon**  
**Nathalie Ahlström**  
**Brian Montgomery**



For personal use only

# Performance Overview

Neil Salmon

For personal use only



# Strong Delivery Against Key Performance Objectives



For personal use only

## Our Previously Stated FY26 Goals

**Organic Constant Currency<sup>2</sup> sales growth**

- ~ Subdued end market conditions
- ~ Organic CC<sup>2</sup> sales decline of 0.6%, improving to adjusted sales growth<sup>3</sup> of 2.1% after excluding ~\$27m of previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability

**Pricing to offset higher US tariffs**

- ✓ All price increases activated, tariff effects offset
- ✓ US business trading in line with expectations

**Earnings supported by higher sales, improved manufacturing and supply chain productivity, and a step up in KBU synergies**

- ✓ Strong expansion in GPADE Margin
- ✓ Increased KBU net cost synergies, on track to deliver ~\$12m in FY26
- ✓ APIP savings target fully achieved

**Strong Cash Conversion<sup>5</sup>**

- ✓ Cash Conversion<sup>5</sup> of 112%, funding share buyback of \$47m and supporting reduction in Net Debt/EBITDA<sup>6</sup> to 1.5x

**Guidance range for Adjusted EPS<sup>4</sup> of US137¢ to US149¢ (upgraded at October 2025 AGM)**

- ✓ Guidance range maintained at US137¢ to US149¢

## FY26 H1 Performance

## Summary Financials

(\$m) <sup>1</sup>	FY26 H1	% Δ	Organic CC % Δ <sup>2</sup>
<b>Sales</b>	<b>1,026.6</b>	<b>0.7%</b>	<b>(0.6%)</b>
<b>GPADE</b>	<b>358.9</b>	<b>7.4%</b>	<b>6.2%</b>
Margin	35.0%	220bps	230bps
<b>EBIT<sup>4</sup></b>	<b>146.9</b>	<b>15.3%</b>	<b>15.4%</b>
Margin	14.3%	180bps	210bps
<b>Adjusted EPS<sup>4</sup> (US¢)</b>	<b>66.3</b>	<b>19.0%</b>	<b>18.5%</b>
<b>Statutory EPS (US¢)</b>	<b>61.5</b>	<b>62.7%</b>	
<b>DPS (US¢)</b>	<b>26.60</b>	<b>19.8%</b>	
<b>Net Debt/EBITDA<sup>6</sup></b>	<b>1.5x</b>		

1. Financials presented in US dollars millions on all slides of this presentation unless otherwise specified
2. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details
3. Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840
4. Before Significant Items
5. Cash Conversion is defined as the percentage of net receipts from operations, excluding Significant Items, to EBITDA, and normalised for the timing of incentive and insurance payments
6. Net Debt/EBITDA is based on LTM EBITDA, excluding Significant Items

### Stated Pricing Objective



#### Pricing to offset higher US tariffs

- Total annualised cost ~\$80m



### Pricing Implementation Status



#### All tariff-related price increases activated

- First wave of price increases completed in June 2025
- Activation of second wave from October 2025, all increases now announced



### US Trading Performance



#### US business trading in line with expectations

Price increases offset combined effect of higher tariff costs and lower demand in tariff-affected verticals, in particular automotive manufacturing

- Negative demand effects also observed in other countries, particularly in Mexico



## Continued Success With New Products In Industrial

## Industrial Segment – Summary Financials

(\$m)	FY25 H1	FY26 H1	% Δ	Org CC <sup>1</sup> % Δ
Sales	457.4	467.9	2.3%	1.2%
EBIT	70.9	83.9	18.3%	16.0%
EBIT/Sales	15.5%	17.9%		

## FY26 H1 Sales Growth % Δ

Org CC<sup>1</sup>Adjusted<sup>2</sup>

Mechanical

2.3% → 5.9%

Chemical

(2.1%) → (2.1%)

Total Industrial

1.2% → 3.4%

For personal use only



## Sales Performance

- Adjusted sales growth<sup>2</sup> of 3.4% in subdued market conditions, supported by tariff-related pricing in the US and higher sales in Mechanical
- Mechanical growth included continued success with new HyFlex® ultra-lightweight cut and Ringers® impact protection products
- Growth in protective clothing in Chemical, offset by lower gloves sales

## EBIT Performance

- Organic CC<sup>1</sup> EBIT growth from higher sales, increased KBU synergies, lower freight costs as the usage of air freight dropped materially versus the prior period, and improved sourcing productivity

# Improvement In Healthcare EBIT Margin

For personal use only

Healthcare Segment – Summary Financials				
(\$m)	FY25 H1	FY26 H1	% Δ	Org CC <sup>1</sup> % Δ
Sales	562.3	558.7	(0.6%)	(2.0%)
EBIT	64.4	72.5	12.6%	15.4%
EBIT/Sales	11.5%	13.0%		
FY26 H1 Sales Growth % Δ		Org CC <sup>1</sup>	Adjusted <sup>2</sup>	
Exam/SU		(2.9%)	(2.9%)	
Surgical		(3.1%)	7.2%	
Cleanroom		2.8%	2.8%	
<b>Total Healthcare</b>		<b>(2.0%)</b>	<b>1.1%</b>	

1. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details

2. Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840



## Sales Performance

- Adjusted sales growth<sup>2</sup> of 1.1%, with tariff-related pricing in the US and higher sales in Surgical partially offset by lower volumes in Exam/SU
- Exam/SU growth in more differentiated industrial single use products offset by lower sales of lower margin medical exam gloves
- Strong Surgical growth, driven by continued higher demand for synthetic products
- Continued growth in Cleanroom safety solutions

## EBIT Performance

- Organic CC<sup>1</sup> EBIT growth from increased KBU synergies, lower freight costs as the usage of air freight dropped materially versus the prior period, and improved sourcing productivity

# Key Growth Drivers & Sustainability Update

Neil Salmon

For personal use only



# Accomplishments Of Last Four Years Better Position Ansell For Long Term Growth

For personal use only

## Success With Digital Transformation, Improving Reliability & Agility

**Enhanced digital capabilities** foundational to accelerated sales growth, productivity gains and improved operating effectiveness

**Unification of ERP systems in majority of manufacturing plants**, paving way for commercial system upgrades and single company ERP solution



## Leaner, More Productive & Customer Focused Organisation

APIP embedded **lower cost and more customer focused organisational structure**

**Growth strategies better grounded in customer insights**, supported by more focused global product teams




## Strengthened Business Processes & Operating Effectiveness

**Improved demand planning capabilities**, supported by better analytics

**Gains in service metrics**, with improved customer experience evident in recognition from key channel partners

**Consistent track record of key project delivery** including accelerated KBU integration



## Increased Presence In Higher Growth Markets & Enhanced Differentiation

**KBU acquisition increased presence in attractive Scientific market**, exited undifferentiated lower margin product lines

**Growing momentum from new products** addressing previously unmet customer safety needs

**Strengthened service differentiation** with capabilities most competitors can't match



# Sales Supported By New Product Launches

## Innovation Focus Areas

### Comfort

Products that are **comfortable to wear** and **support hand & skin health**

### Performance & Productivity

**Longer lasting** products supporting **job performance & worker productivity**

### Protection

**Enhanced protection**, multi-hazard solutions combining **protection needs**

### Sustainability

**Environmentally-friendly** materials and manufacturing processes

For personal use only

## Key FY26 New Products

**HyFlex®** | 11-574 / 11-584 / 11-594 / 11-814 / 11-844  
Precision comfort series with AEROFIT™

Multi-purpose and cut protection gloves offering a second-skin fit for exceptional comfort and tactile control.



**Ringers Gloves** | R570 / R580 / R590  
Light duty impact-resistant gloves

Providing reliable impact and cut protection in a lightweight, flexible design that ensures comfort throughout the day, boosting productivity and reducing costs.



**TouchNTuff®** | 93-800  
Nitrile disposable glove

The first disposable glove to be resistant to acetone for at least 15 minutes, providing superior protection against acetone exposure and enhanced resistance to other harsh chemicals for workers in a wide range of industrial environments.



**AlphaTec®** | 58-005 / 58-735 / 58-835  
High-end chemical protective gloves, with cut protection

Providing combined chemical and cut protection, comfort and durability for workers exposed to chemical hazards and handling sharp objects in a wide range of manufacturing industries.



**AlphaTec®** | Phantom  
PFAS-free tactical suit for first response, hazmat and CBRN operations

Providing excellent protection against chemical and biological warfare agents as well as toxic industrial chemicals. Tested and approved in accordance with NFPA 1994 (1990) Class 1 & 2.



# Further Enhancing Customer Intimacy Through Investment In Leading Service Solutions

For personal use only

## AnsellGUARDIAN®

**Data-driven, proprietary PPE assessment** used by our safety experts to provide customers with **tailored product recommendations based on their specific needs**, including safety, compliance, productivity and sustainability


- ✓ Deploying AI to enhance report preparation speed and enrich dataset
- ✓ ~1,200 audits completed in FY26 H1, +30% versus FY25 H1



## AnsellGUARDIAN™ Chemical

Digital suite of tools that **simplifies the chemical PPE selection process for an organisation**, based on its specific chemicals and applications

- ✓ Integrating AI safety data sheet reader, saving significant sales force time
- ✓ Expanding database to >130,000 chemicals
- ✓ >24,000 Chemical Guardian queries in FY26 H1, strong growth in North America & EMEA



## RightCycle™

**Product recycling service that reduces waste to landfill** for non-hazardous laboratory, cleanroom and industrial PPE waste

- ✓ Broadening to include Industrial products
- ✓ European roll out in progress
- ✓ >260 tons of used PPE recycled in FY26 H1, +28% versus FY25 H1



## Our 2040 Sustainability Action Plan Targets

## FY26 H1 Progress

## People



## Reduce TRIFR

**100% of direct suppliers<sup>1</sup> to meet Ansell's labour, health and safety standards by FY27**

- ✓ Reduction in recordable accidents
- ✓ Increase in number of finished goods and raw material suppliers included in our Supplier Management Framework

## Planet

Net zero emissions by FY45<sup>2</sup>, including scope 3Reduce water withdrawals by 35% by end of FY27<sup>3</sup>

## Zero waste to landfill for all manufacturing plants

## Improve environmental stewardship – fully compliant with EU Deforestation Regulation for natural rubber latex traceability

- ✓ Decrease in Scope 1 & 2 emissions
- ✓ Decrease in water withdrawals, on improved water usage practices and lower production
- ✓ Original scope facilities certified. Certification of new sites by 2027
- ✓ Ready for deployment in FY27 when the regulation becomes applicable

## Products

Design 80% of new and updated products with reduced environmental impact by FY26<sup>4</sup>

- ✓ New products include HyFlex® sustainable high cut product family featuring >50% recycled content

1. In-scope suppliers based on Ansell's Supplier Management Framework

2. Less than 10% use of offsets

3. Versus FY20 baseline

4. Performance is measured according to Design for Sustainability (D4S) principles when compared with gloves of a similar make

# Financial Results

*Brian Montgomery*

For personal use only



## Double-Digit Earnings Growth

## P&amp;L Summary

(\$m)	FY25 H1	FY26 H1	% Δ	Org CC <sup>1</sup> % Δ
<b>Sales</b>	<b>1,019.7</b>	<b>1,026.6</b>	<b>0.7%</b>	<b>(0.6%)</b>
Cost of Goods Sold	(620.9)	(605.3)	(2.5%)	(3.8%)
Distribution Costs	(64.7)	(62.4)	(3.6%)	(5.6%)
<b>GPADE</b>	<b>334.1</b>	<b>358.9</b>	<b>7.4%</b>	<b>6.2%</b>
SG&A	(206.7)	(212.0)	2.6%	0.4%
<b>EBIT<sup>3</sup></b>	<b>127.4</b>	<b>146.9</b>	<b>15.3%</b>	<b>15.4%</b>
Significant Items <sup>4</sup>	(30.3)	(7.3)	(75.9%)	
Net Interest	(19.9)	(20.2)	1.5%	0.5%
Taxes	(21.0)	(30.1)	43.3%	23.3%
Minority Interests	(1.2)	(0.5)	(58.3%)	(61.5%)
<b>Statutory Profit Attributable</b>	<b>55.0</b>	<b>88.8</b>	<b>61.5%</b>	
<b>Adjusted Profit Attributable<sup>3</sup></b>	<b>81.0</b>	<b>95.7</b>	<b>18.1%</b>	<b>17.7%</b>
GPADE/Sales	32.8%	35.0%		
SG&A/Sales	20.3%	20.7%		
EBIT/Sales	12.5%	14.3%		
Adjusted Effective Tax Rate <sup>3</sup>	23.5%	24.1%		
<b>Statutory EPS (US¢)</b>	<b>37.8¢</b>	<b>61.5</b>	<b>62.7%</b>	
<b>Adjusted EPS<sup>3</sup> (US¢)</b>	<b>55.7¢</b>	<b>66.3</b>	<b>19.0%</b>	<b>18.5%</b>

For personal use only

1. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details
2. Adjusted sales growth excludes previously disclosed sales in FY25 H1 that benefitted from temporary order pattern favourability from the Organic CC calculation, including ~\$17m in Healthcare from the fulfilment of surgical orders unable to be shipped in FY24 due to Red Sea disruptions, and ~\$10m in Industrial from customers increasing safety stocks of the Ringers® R840
3. Before Significant Items
4. Significant Items in FY26 H1 includes \$5.4m one-off costs associated with the Accelerated Productivity Investment Program and \$1.9m other costs including legal costs associated with the shareholder class action. Significant Items in FY25 H1 includes \$6.4m one-off costs associated with the Accelerated Productivity Investment Program, \$10.0m one-off costs associated with the KBU transaction, \$12.9m one-off costs associated with the KBU integration, and \$1.0m other costs including legal costs associated with the shareholder class action

## Key Comments

- Organic CC<sup>1</sup> sales decline of 0.6%, improving to adjusted sales growth<sup>2</sup> of 2.1%
  - Adjusted sales growth<sup>2</sup> supported by tariff-related pricing in the US, partially offset by lower Exam/SU volumes in Healthcare
- GPADE margin increased 220bps
  - Margin accretion from lower freight costs and improved sourcing productivity
  - Combination of tariff-related pricing and higher tariff costs moderately dilutive to GPADE margin
- 0.4% Organic CC<sup>1</sup> SG&A growth, with higher employee costs partially offset by increased KBU cost synergies
- FX unfavourable to EBIT by \$1.6m, favourable translation effects offset by higher hedge contract losses versus FY25 H1
- Reduction in Significant Items<sup>4</sup> versus FY25 H1 following completion of KBU transaction and integration in FY25
- Adjusted effective tax rate<sup>3</sup> of 24.1%, in line with guidance

# Healthy Balance Sheet

## Balance Sheet Summary

(\$m)	Dec-24	Jun-25	Dec-25
Fixed Assets	362.1	377.2	404.0
Intangibles	1,638.2	1,655.5	1,655.1
Right of Use Assets	81.9	98.4	90.1
Other Assets/Liabilities	(56.0)	(136.4)	(99.1)
<b>Working Capital<sup>1</sup></b>	<b>453.7</b>	<b>558.2</b>	<b>535.7</b>
Inventories	525.4	584.7	577.2
Receivables <sup>1</sup>	162.2	212.4	191.3
Payables <sup>1</sup>	233.9	238.9	232.8
<b>Capital Employed</b>	<b>2,479.9</b>	<b>2,552.9</b>	<b>2,585.8</b>
<b>Net Debt</b>	<b>556.8</b>	<b>570.2</b>	<b>583.0</b>
<b>Shareholders' Funds</b>	<b>1,923.1</b>	<b>1,982.7</b>	<b>2,002.8</b>
ROCE % (Pre-Tax) <sup>2</sup>	11.1%	12.8%	11.9%
ROE % (Post-Tax) <sup>3</sup>	9.3%	9.5%	10.1%

For personal use only


1. Trade receivables and trade payables have had GST/VAT receivable and payable balances reclassified to other receivables and other payables
2. ROCE % calculated as LTM EBIT over average capital employed. LTM EBIT is adjusted to exclude Significant Items
3. ROE % calculated as LTM Profit Attributable over average shareholder funds. LTM Profit Attributable is adjusted to exclude Significant Items

## Key Comments

- Strong balance sheet with Moody's Baa2 investment grade rating
- Improvement in working capital versus Jun-25
  - Reduction in inventory despite capitalisation of higher tariff costs in the US
  - Improvement in receivables largely due to collections seasonality, small reduction in payables due to lower purchases from outsourced finished goods suppliers
- Dec-25 ROCE includes full allocation of KBU capital employed, representing a ~70 basis point improvement versus Jun-25 on a like-for-like basis
  - Note KBU capital employed and equity funding only partially accounted for in Dec-24 and Jun-25 ROCE and ROE calculations, due to denominator averaging

Strong Cash Conversion<sup>1</sup>

For personal use only



1. Cash Conversion is defined as the percentage of net receipts from operations, excluding Significant Items, to EBITDA, and normalised for the timing of incentive and insurance payments

2. Includes Significant Items

3. Operating Cash Flow is defined as net receipts from operations per the Consolidated Statement of Cash Flows adjusted for net payments for property, plant and equipment and intangible assets, repayments of lease liabilities, net interest paid, and tax paid

### Key Comments

- Cash Conversion<sup>1</sup> of 112%, after normalising for the timing of incentive and insurance payments
- Working capital inflow on improved collections and lower inventory
- Other item bridging EBITDA to Net Receipts includes FY25 incentive payments made in Sep-25
- Net capex of \$28.2m included dipping line installations in our greenfield India Surgical facility
- Strong cash flow funded \$47.2m share buyback
- FY26 acquisitions outflow reflects acquisition of controlling interest in key manufacturing site in Sri Lanka. FY25 reflects acquisition of KBU

# Significant Liquidity & Balance Sheet Capacity To Fund Growth Investments & Capital Management

## Net Debt Summary

(\$m)	Dec-24	Jun-25	Dec-25
Interest-Bearing Debt	737.7	698.9	733.8
Cash at Bank and Short-Term Deposits	268.9	235.4	250.7
<b>Net Interest-Bearing Debt (NIBD)</b>	<b>468.8</b>	<b>463.5</b>	<b>483.1</b>
Lease Liabilities	88.0	106.7	99.9
<b>Net Debt</b>	<b>556.8</b>	<b>570.2</b>	<b>583.0</b>
Net Debt/EBITDA <sup>1</sup>	1.8x	1.6x	1.5x
Pro Forma Net Debt/EBITDA <sup>2</sup>	1.6x	n/a	n/a


1. Net Debt/EBITDA is based on LTM EBITDA, excluding Significant Items

2. Pro Forma Net Debt/EBITDA for 31-Dec-24 includes KBU EBITDA for the six months from Jan-Jun 2024

## Key Comments

- Reduction in Net Debt/EBITDA to 1.5x driven by strong earnings growth and working capital management
- Significant liquidity with \$719m of cash and undrawn bank facilities
- Debt profile has an average maturity tenor of 5.1 years
- 66% of debt facilities are at fixed interest rates, average interest rate on borrowings of 4.75%
- Substantial headroom within debt financial covenants which combined with strong liquidity and cash generation provides financial flexibility to fund a combination of internal investments, M&A and capital management

## Drawn Debt Maturity Profile (\$m)



# FY26 Outlook

Nathalie Ahlström

For personal use only



# Initial Observations As Incoming CEO

## **Nathalie Ahlström has been appointed by the Board of Directors as Ansell's new Managing Director and CEO**

"I'm honored to take on the role of CEO at Ansell. Across its 130-year history, Ansell has developed into a global leader in safety, innovating solutions that safeguard lives and enable businesses to thrive. That legacy of trust and impact is extraordinary, and it is a privilege to help shape its next chapter.

What drew me to Ansell is not only its leadership in protective solutions, but its unwavering commitment to a bold and meaningful vision: **Leading the world to a safer future.** This is more than a statement, it's a promise to protect lives, empower communities, and shape a future where safety enables progress everywhere.

Ansell's future is bright. Together, we will advance innovation, deliver sustainable growth, and make a positive impact on the world, while creating long-term value for our shareholders."



# Key Priorities For Remainder Of FY26


For personal use only

## Driving Sales Growth

Build momentum from highly differentiated new product launches

Commercialise AI-enabled services enhancements

Continue to monitor trade policy developments and tariff-related demand effects



## Improving Productivity

Deliver KBU cost synergies

Advance manufacturing automation investments

Prepare for implementation of ERP system upgrades, starting in North America



## Advancing Sustainability

Sustain improvements in safety metrics

Demonstrate effectiveness of reverse osmosis water recycling

Broaden scope of Supplier Management Framework



## Cash Flows & Capital Management

Maintain strong cash conversion

Continue with previously announced on-market share buyback program



# Guidance Range For FY26 Adjusted EPS<sup>1</sup> Maintained At US137¢ to US149¢

For personal use only

**Sales**

Stable end market conditions, increased sales

**Adjusted EPS<sup>1</sup>**

Earnings growth from higher sales, improved manufacturing and supply chain productivity, and a step up in KBU synergies

**Cash Flow**

Strong cash conversion and continued balanced approach to capital allocation

**What We Expect To See****Guidance Assumptions**

- Expecting organic constant currency<sup>2</sup> sales growth in FY26 H2
  - Market conditions expected to remain unchanged
  - Unmatched global presence and end-user focused sales approach provides growth opportunities in favoured verticals and geographies
- On track to deliver incremental KBU net pre-tax cost synergies of ~\$7m versus FY25, bringing total FY26 net pre-tax cost synergies to ~\$12m
- FX headwind to EBIT of ~\$5m versus FY25, favourable currency movements offset by hedge book losses of >\$10m
- Net interest cost of ~\$43m
- Book tax rate of 23.5% to 24.5%
- One-off pre-tax costs (Significant Items, excluded from Adjusted EPS<sup>1</sup>) of ~\$15m, primarily in relation to ERP system upgrades within the scope of APIP
- Capex of \$60m to \$70m
- Continuation of on-market share buyback program in FY26 H2

1. Before Significant Items

2. Organic CC (Constant Currency) compares FY26 H1 to FY25 H1 at Constant Currency and adjusts for the effects of acquisitions, divestments and business exits including the contribution from exited product groups that are no longer sold in FY26. Refer to slide 28 for further details

## Q&A

Neil Salmon

Nathalie Ahlström

Brian Montgomery

For personal use only



## Appendix

For personal use only



# APIP Update: Savings Goal Achieved, Preparing For Commercial ERP System Upgrades

For personal use only

## Organisation

### Simplify & Streamline Our Organisational Structure



- ✓ Changes completed in FY24
- ✓ Reorganised customer units benefiting from enhanced focus and contributing to improved sales momentum

## Manufacturing

### Improve Manufacturing Productivity



- ✓ Changes completed in FY25
- ✓ Gains in manufacturing productivity evident in GPADE margin expansion

## IT

### Accelerate Digitisation Strategy



- ✓ Multiple rounds of testing completed ahead of planned go live of upgraded ERP system in North America in coming months
- ✓ Other regions planned to cutover through FY27 and FY28

## Summary Financials

### APIP Savings

(annual versus FY23 baseline)

Annualised savings over the last 12 months total \$50m – total program savings goal achieved

### APIP Cash Costs

**FY24:** \$44m  
**FY25:** \$15m  
**FY26 H1:** \$5m  
**Total Incurred:** \$64m  
**Total Program Forecast:** \$85-90m, including \$35m of IT costs

# Sales & EBIT Impact Of FX Movements

For personal use only


	FX Impact (\$m)		Key Comments
	Sales	EBIT	
<b>FY26 H1 vs FY25 H1</b>			
FX Rate Movements	21.1	4.4	<ul style="list-style-type: none"> <li>Net improvement in Sales and EBIT, large positive movement in the EUR partially offset by adverse movements in the MYR and THB</li> </ul>
FX Gain/(Loss) Variance – Hedge Contracts		(6.0)	<ul style="list-style-type: none"> <li>Net foreign exchange loss on hedge contracts in FY26 H1 was \$7.8m, the equivalent number in FY25 H1 was a loss of \$1.8m</li> </ul>
<b>Total</b>	<b>21.1</b>	<b>(1.6)</b>	
<b>FY26 H2 Forecast vs FY25 H2</b>			
FX Rate Movements	~19	~2	<ul style="list-style-type: none"> <li>Based on our foreign exchange rate assumptions, we anticipate a positive net currency movement in FY26 H2, primarily driven by the EUR, partially offset by adverse movements in the MYR and THB</li> </ul>
FX Gain/(Loss) Variance – Hedge Contracts		~(5)	<ul style="list-style-type: none"> <li>Favourable currency movement offset by expected losses on hedge contracts</li> </ul>
<b>Total</b>	<b>~19</b>	<b>~(3)</b>	
<b>FY26 Forecast vs FY25</b>	<b>~40</b>	<b>~(5)</b>	

### FY26 H1 Input Cost Trends


For personal use only

- Decline in NBR and NRL costs versus FY25 H1, as well as synthetics and yarns
- Employee cost inflation persists in key manufacturing locations, including additional social compliance costs. Continued focus on productivity improvements to offset, including investment in automation technologies
- Energy costs stable
- Reduction in Exam/SU outsourced finished goods costs, on lower NBR costs
- Strengthening in key cost currencies including the MYR and THB

#### FY26 H1 COGS Components (COGS \$605.3m)



#### FY26 H1 Raw Material Mix



### Constant Currency

For personal use only

- The presentation of constant currency information is designed to facilitate comparability of reported earnings by restating the prior period's results at the exchange rates applied in determining the results for the current period. This is achieved by analysing and estimating, where necessary, revenue and cost transactions by the underlying currencies of our controlled entities. These transactions are converted to US dollars at the average exchange rates applicable to the current period on a month-by-month basis (Currency Effect). In addition, the profit and loss impact of net foreign exchange gains/losses is excluded from the current and prior year's results (Net Exchange Loss).
- The principles of constant currency reporting and its implementation are subject to oversight by the Audit and Compliance Committee of the Board. It is considered as supplemental non-IFRS financial information.

### Organic Constant Currency

- Organic constant currency compares the current period's performance to the prior period's results on a constant currency basis with organic adjustments, such as the effects of acquisitions, divestments, and business exits, including the contribution from exited product groups that are no longer sold in FY26.

### Restated Prior Period (\$m)

	Industrial	Healthcare	Corporate	Group
<b>Prior Period Sales</b>				
<b>Reported Sales</b>	<b>457.4</b>	<b>562.3</b>	<b>0.0</b>	<b>1,019.7</b>
Less Exited Product Group	(6.3)	(2.0)	0.0	(8.3)
Remove Currency Effect	11.4	9.7	0.0	21.1
<b>Organic Constant Currency Sales</b>	<b>462.5</b>	<b>570.0</b>	<b>0.0</b>	<b>1,032.5</b>
<b>Prior Period EBIT</b>				
<b>Reported EBIT</b>	<b>70.9</b>	<b>64.4</b>	<b>(7.9)</b>	<b>127.4</b>
Less Exited Product Group	0.0	0.4	0.0	0.4
Remove Currency Effect	3.8	0.6	0.0	4.4
Remove Net Exchange Loss	0.8	1.0	0.0	1.8
<b>Organic Constant Currency EBIT</b>	<b>75.5</b>	<b>66.4</b>	<b>(7.9)</b>	<b>134.0</b>
<b>Prior Period Profit Attributable</b>				
<b>Reported Profit Attributable</b>				<b>55.0</b>
Remove Significant Items				26.0
<b>Adjusted Profit Attributable</b>				<b>81.0</b>
Less Exited Product Group				0.3
Remove Currency Effect				3.2
Remove Net Exchange Loss				1.5
<b>Organic Constant Currency Profit Attributable</b>				<b>86.0</b>

For personal use only

(\$m)		FY16 <sup>1</sup>	FY17 <sup>1</sup>	FY18 <sup>1</sup>	FY19 <sup>1</sup>	FY20 <sup>1</sup>	FY21 <sup>1</sup>	FY22	FY23	FY24	FY25	1H20 <sup>1</sup>	1H21 <sup>1</sup>	1H22	1H23	1H24	1H25	1H26
<b>Ansell</b>																		
Sales		1,352.8	1,374.5	1,489.8	1,499.0	1,613.7	2,026.9	1,952.1	1,655.1	1,619.3	2,003.3	753.3	937.8	1,009.2	835.3	784.9	1,019.7	1,026.6
EBIT <sup>2,3,4,5,6,7</sup>		188.2	178.4	193.43	200.9	216.7	338.0	245.1	206.3	195.5	282.1	90.0	146.7	111.0	91.5	78.2	127.4	146.9
% Margin <sup>3,4,5,6,7</sup>		13.9%	13.0%	13.0%	13.4%	13.4%	16.7%	12.6%	12.5%	12.1%	14.1%	11.9%	15.6%	11.0%	11.0%	10.0%	12.5%	14.3%
<b>Segments</b>																		
Industrial	Sales	654.8	655.9	715.5	703.7	719.1	790.7	762.5	750.9	785.1	898.6	358.4	388.1	377.1	368.3	384.4	457.4	467.9
	EBIT <sup>2,3,4,5,6,7</sup>	82.8	79.8	86.9	98.7	92.4	112.4	107.0	103.9	129.3	155.5	44.4	57.9	56.3	42.8	58.2	70.9	83.9
	% Margin <sup>3,4,5,6,7</sup>	12.6%	12.2%	12.1%	14.0%	12.8%	14.2%	14.0%	13.8%	16.5%	17.3%	12.4%	14.9%	14.9%	11.6%	15.1%	15.5%	17.9%
Healthcare	Sales	698.0	718.6	774.3	795.3	894.6	1,236.2	1,189.6	904.2	834.2	1,104.7	394.9	549.7	632.1	467.0	400.5	562.3	558.7
	EBIT <sup>2,3,4,5,6,7</sup>	116.5	110.1	120.1	115.3	141.8	248.8	150.7	113.4	81.1	141.9	54.6	100.4	63.7	55.9	27.3	64.4	72.5
	% Margin <sup>3,4,5,6,7</sup>	16.7%	15.3%	15.5%	14.5%	15.9%	20.1%	12.7%	12.5%	9.7%	12.8%	13.8%	18.3%	10.1%	12.0%	6.8%	11.5%	13.0%
Corporate Costs		(11.1)	(11.5)	(13.6)	(13.1)	(17.5)	(23.2)	(12.6)	(11.0)	(14.9)	(15.3)	(9.0)	(11.6)	(9.0)	(7.2)	(7.3)	(7.9)	(9.5)

1. FY16-FY21 have been adjusted or restated retrospectively to apply the accounting policy change upon adoption of the April 2021 IFRIC Agenda Decision 'Configuration or Customisation Costs in a Cloud Computing Arrangement (IAS 38 Intangible Assets)'. Please note adjustments are included in Corporate Costs
2. FY16 Segment EBIT adjusted to include overhead costs previously allocated to Sexual Wellness and revised allocation methodology appropriate to new segments
3. EBIT and % Margin for FY18 and FY19 adjusted to exclude transformation costs and non-recurring items
4. EBIT and % Margin for FY22 and FY23 adjusted to exclude Russia exit costs
5. EBIT and % Margin for FY24 adjusted to exclude one-off costs associated with the Accelerated Productivity Investment Program, the KBU acquisition and integration, and legal costs associated with the shareholder class action
6. EBIT and % Margin for FY25 adjusted to exclude one-off costs associated with the Accelerated Productivity Investment Program, the KBU acquisition and integration, a non-cash charge against the value of retired brands, and legal costs associated with the shareholder class action
7. EBIT and % Margin for FY26 H1 adjusted to exclude one-off costs associated with the Accelerated Productivity Investment Program and legal costs associated with the shareholder class action

### Key Figures

- Booked tax losses at 31 December 2025: \$23.9m
- Unbooked tax losses at 31 December 2025: \$17.3m (tax-effected)
- Unbooked capital losses at 31 December 2025: \$76.7m
- Interest rate on borrowings at 31 December 2025: 4.75% p.a.
- FY26 interim dividend: US26.60¢ per share (FY25 interim dividend US22.20¢ per share)
- Ordinary shares issued at 31 December 2025: 143.8m (145.9m at 31 December 2024)
- Weighted average no. of shares for FY26 H1 Adjusted EPS<sup>1</sup> calculation: 144.3m (145.4m for FY25 H1)

### Key FY26 Assumptions

- Foreign exchange exposures by currency:  
Revenue currencies: USD 55%, EUR 26%, CAD 4%, GBP 4%, CNY 3%, AUD 3%  
Cost currencies: USD 63%, EUR 10%, MYR 10%, THB 6%, AUD 2%, CNY 2%
- Net interest cost of ~\$43m
- Tax rates, excluding one-off costs:  
Book tax rate: 23.5% to 24.5%  
Cash tax rate: 20% to 21%
- One-off pre-tax costs (Significant Items, excluded from Adjusted EPS<sup>1</sup>) of ~\$15m, primarily in relation to ERP system upgrades within the scope of APIP
- Capex of \$60m to \$70m

For personal use only

AI – Artificial Intelligence

APIP – Accelerated Productivity Investment Program

AUD – Australian Dollar

CAD – Canadian Dollar

Capex – Capital Expenditure

CC – Constant Currency

CNY – Chinese Yuan

COGS – Cost of Goods Sold

DPS – Dividend Per Share

EBIT<sup>1</sup> – Earnings Before Interest & TaxEBITDA<sup>1</sup> – Earnings Before Interest, Tax, Depreciation and Amortisation

EPS – Earnings Per Share

ERP – Enterprise Resource Planning

EUR – Euro

FX – Foreign Exchange

FY – Financial Year (July – June)

GBP – Great British Pound

GPADE – Gross Profit After Distribution Expenses

H1 – First Half (July – December)

H2 – Second Half (January – June)

IFRIC – IFRS Interpretations Committee

KBU – Ansell's Kimtech™ and KleenGuard™ Business Unit (formerly Kimberly-Clark Corporation's Personal Protective Equipment Business)

LTM – Last 12 Months

MYR – Malaysian Ringgit

NBR – Nitrile Butadiene Rubber

NIBD – Net Interest-Bearing Debt

NRL – Natural Rubber Latex

ROCE – Return On Capital Employed

ROE – Return On Equity

Significant Items<sup>2</sup> – income or expense items that are unusual or infrequent, also known as non-recurring

SG&amp;A – Selling, General and Administrative Expenses

SU – Single Use

THB – Thai Baht

TRIFR – Total Recordable Injury Frequency Rate

USD – United States Dollar

1. EBITDA and EBIT exclude Significant Items

2. Includes one-off costs associated with the Accelerated Productivity Investment Program and legal costs associated with the shareholder class action in FY26 H1. Includes one-off costs associated with the Accelerated Productivity Investment Program and the KBU transaction and integration, and legal costs associated with the shareholder class action in FY25 H1

For personal use only



Lead the world to a safer future.

[www.ansell.com](http://www.ansell.com)